Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates - The VIVA II study

Journal of International Medical Research

Volumn 37, Issue 4, 2009, Pages 1225-1229

  Payer, J ^a   Cierny D ^a   Killinger, Z ^a   Sulkova I ^a   Behuliak, M ^a   Celec, Peter ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

Adherence; Bisphosphonates; Comfort; Convenience; Once monthly; Osteoporosis; Simplicity

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; FEMALE; FRIEND; GASTROINTESTINAL SYMPTOM; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MASS COMMUNICATION; MEDICAL INFORMATION; MOTIVATION; MUSCLE DISEASE; NUTRITION; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; QUESTIONNAIRE; RELATIVE; CONSUMER HEALTH INFORMATION; DRUG ADMINISTRATION; INFORMATION DISSEMINATION; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT;

BONE DENSITY CONSERVATION AGENTS; CONSUMER HEALTH INFORMATION; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFORMATION DISSEMINATION; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 70350506545     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700430     Document Type: Article

References (11)

1. Curtis JR, Westfall AO, Cheng H, et al: Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101 038 new bisphosphonate users. J Bone Miner Res 2008; 23: 1435-1441.
2. Bauss F, Schimmer RC: Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag 2006; 2: 3-18. (Pubitemid 43950061)
3. Payer J, Killinger Z, Sulková I, et al: Preferences of patients receiving bisphosphonates - how to influence the therapeutic adherence. Biomed Pharmacother 2008; 62: 122-124. (Pubitemid 351215813)
4. Emkey R, Koltun W, Beusterien K, et al: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21: 1895-1903. (Pubitemid 41803098)
5. Hadji P, Minne H, Pfeifer M, et al: Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2008; 75: 303-310.
6. Papaioannou A, Kennedy CC, Dolovich L, et al: Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24: 37-55. (Pubitemid 46148080)
7. Briesacher BA, Andrade SE, Fouayzi H, et al: Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28: 437-443.
8. Lau E, Papaioannou A, Dolovich L, et al: Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 2008; 54: 394-402.
9. Chapurlat RD: Single annual injectable treatment for postmenopausal osteoporosis. Expert Opin Drug Deliv 2008; 5: 583-591. (Pubitemid 351877435)
10. Lewiecki EM: Intravenous zoledronic acid for the treatment of osteoporosis. Curr Osteoporos Rep 2008; 6: 17-23.
11. Kertes J, Dushenat M, Vesterman JL, et al: Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 2008; 10: 207-213. (Pubitemid 351649619)